They also have implications for the development of therapeutic approaches to inhibit IL17 driven inflammatory diseases, since inhibitors targeting ITK may have utility for some diseases where Th17 cells have a role, there may be other diseases, such as SR-driven HP, where they may have less utility. This evidence concerns the gene IL17A and hypersensitivity pneumonitis.